HomeCompareEARS vs QSR

EARS vs QSR: Dividend Comparison 2026

EARS yields 65.68% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EARS wins by $832.8K in total portfolio value
10 years
EARS
EARS
● Live price
65.68%
Share price
$3.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$857.5K
Annual income
$214,640.91
Full EARS calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.76
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$387.88
Full QSR calculator →

Portfolio growth — EARS vs QSR

📍 EARS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEARSQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EARS + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EARS pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EARS
Annual income on $10K today (after 15% tax)
$5,582.92/yr
After 10yr DRIP, annual income (after tax)
$182,444.77/yr
QSR
Annual income on $10K today (after 15% tax)
$289.25/yr
After 10yr DRIP, annual income (after tax)
$329.70/yr
At 15% tax rate, EARS beats the other by $182,115.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EARS + QSR for your $10,000?

EARS: 50%QSR: 50%
100% QSR50/50100% EARS
Portfolio after 10yr
$441.1K
Annual income
$107,514.39/yr
Blended yield
24.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

EARS
No analyst data
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.6% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EARS buys
0
QSR buys
0
No recent congressional trades found for EARS or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEARSQSR
Forward yield65.68%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$857.5K$24.7K
Annual income after 10y$214,640.91$387.88
Total dividends collected$722.8K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock

Year-by-year: EARS vs QSR ($10,000, DRIP)

YearEARS PortfolioEARS Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$17,268$6,568.14$11,038$337.57+$6.2KEARS
2$29,077$10,599.97$12,156$345.43+$16.9KEARS
3$47,793$16,681.04$13,359$352.69+$34.4KEARS
4$76,764$25,624.68$14,654$359.36+$62.1KEARS
5$120,602$38,464.70$16,045$365.45+$104.6KEARS
6$185,521$56,477.71$17,539$370.97+$168.0KEARS
7$279,704$81,195.93$19,143$375.96+$260.6KEARS
8$413,691$114,407.58$20,863$380.42+$392.8KEARS
9$600,792$158,142.40$22,708$384.39+$578.1KEARS
10$857,488$214,640.91$24,685$387.88+$832.8KEARS

EARS vs QSR: Complete Analysis 2026

EARSStock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Full EARS Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this EARS vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EARS vs SCHDEARS vs JEPIEARS vs OEARS vs KOEARS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.